Stereotaxis, Inc. : Stereotaxis Announces Positive Results from First 50 Clinical Procedures Performed with New Niobe ES™ System

ST. LOUIS, Jan. 10, 2012/PRNewswire/ -- Stereotaxis, Inc. (NASDAQ: STXS) today announced the completion of the first 50 clinical procedures using the Company's new Niobe ES™ system to treat patients with a variety of complex cardiac arrhythmias.  A majority of the first 50 cases were performed to treat atrial fibrillation (AF), the most common type of cardiac arrhythmia(1).  Positive initial results with the Niobe ES system in Europedemonstrate that the average time for completion of mappingablation for the initial AF patients was 69 minutes.  The data will be featured at the Boston Atrial Fibrillation Symposium 2012 to be held on January 12-14, 2012.

The Epoch™ platform, which encompasses the Niobe ES system, is the Company's new generation comprehensive solution for the electrophysiology (EP) laboratory. It is designed to improve efficiency with a fully-remote, networkedmodular robotic, magnetic system that enables greater surgical precisionimproved catheter control while reducing the risk of complications.  Stereotaxis began initial shipments of the Epoch platform in mid-December 2011, including six system upgrades from the Niobe®II navigation system at leading medical centers in the United StatesEurope. 

Professor Carlo Papponeof Villa Maria Cecilia Hospital, Cotignola Italy, said, "My vision was to click on the mapfor the catheter to quicklyprecisely move to that spot.  Today with the Epoch platform, this is a reality.  I believe the Epoch platform is one of the most important innovations for the EP practice to date.  With the Epoch technology all physicians can successfullyconsistently perform high quality AF procedures with the assurance of superior patient care."

THE HEART HOSPITAL Baylor Plano in Plano, Texaswas the first North American site to install the new Epoch platform,the first hospital in the world to perform an EP procedure using the new system.

"Interventional physicians want to leverage advanced technology that minimizes surgical risks to the patient while increasing the likelihood of a favorable outcome," said Brian DeVille, M.D., FACC, eletrophysiologist on the medical staff at THE HEART HOSPITAL Baylor Plano.  "The new Niobe ES system will enable electrophysiologists on the medical staff to deliver therapy in a precise manner, while reducing X-ray exposureprocedure time for our patients."

"The initial feedbackinterest in our new Epoch platform has been very favorable," said Michael P. Kaminski, PresidentCEO of Stereotaxis.  "We look forward to continuing to build on the momentum of this milestonehave commitments for 12 additional system upgrades to Niobe ES which will be installed over the next few months."

Stereotaxis designs, manufacturesmarkets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery diseasearrhythmias. The Niobe®Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of cathetersguidewires through the blood vesselschambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigationreduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recordingnetworking interventional lab information within hospitalsaround the world. Odyssey™ Vision integrates data for magneticstandard interventional labs, enhancing the physician workflow through a consolidated display of multiple systemseliminating the challenge of interacting simultaneously with many separate diagnostic systems. The Odyssey Cinema™ Studio then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ solution then enables hospitals to efficiently share liverecorded clinical data anywhere around the world to attract patientspromote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canadaelsewhere.(1) Niobe ES is cleared for the US but is not approved for treatment for atrial fibrillation. For more information, please visit .

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risksuncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the abilitywillingness of customers to purchase our systemsthe timing of such purchases, our continued access to capitalfinancial resources, including our ability to negotiate financinglending arrangements on terms that are acceptable, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals,other risks discussed in the Company's periodicother filings with the SecuritiesExchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase ordersother commitments in any particular period or at all because some of these purchase ordersother commitments are subject to contingencies that are outside of the Company's control. In addition, these orderscommitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

SOURCE Stereotaxis, Inc.

Company, Sam Duggan, Chief Financial Officer of Stereotaxis, Inc., [phone]; or Investors, Gregory Gin, [phone], or Doug Sherk, [phone], both of EVC Group, Inc., for Stereotaxis, Inc.; or Media, Frank Cheng, Senior Vice President, Marketing & Business Development of Stereotaxis, Inc., [phone]